TCGA-66-2765-01A-01R-0851-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.540
- INTERFERON_ALPHA_RESPONSE+0.510
- MYC_TARGETS_V2+0.460
- ALLOGRAFT_REJECTION+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- INTERFERON_GAMMA_RESPONSE+0.410
- E2F_TARGETS+0.400
- INFLAMMATORY_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
Top 10 suppressed
- KRAS_SIGNALING_DN-0.130
- NOTCH_SIGNALING-0.120
- BILE_ACID_METABOLISM-0.090
- UV_RESPONSE_DN-0.060
- PROTEIN_SECRETION-0.040
- SPERMATOGENESIS-0.020
- WNT_BETA_CATENIN_SIGNALING+0.000
- HEDGEHOG_SIGNALING+0.040
- XENOBIOTIC_METABOLISM+0.040
- ANDROGEN_RESPONSE+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.931 |
| 2 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.931 |
| 3 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.928 |
| 4 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.928 |
| 5 | 2F14C141-CE43-4934-BEC9-769A181DB053 | — | — | 0.925 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.922 |
| 7 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.921 |
| 8 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.919 |
| 9 | TCGA-66-2780-01A-01R-0851-07 | — | cohortSQ1 | 0.914 |
| 10 | 53018DE1-9557-4181-A0F2-5200013F1CEA | — | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |